2024 Q3 Form 10-Q Financial Statement
#000165066424000097 Filed on August 07, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| Revenue | $61.00K | $513.0K |
| YoY Change | -98.86% | -82.23% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $18.09M | $18.21M |
| YoY Change | 20.67% | 5.84% |
| % of Gross Profit | ||
| Research & Development | $47.64M | $54.21M |
| YoY Change | 17.59% | 82.04% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.599M | $1.420M |
| YoY Change | 5.2% | -7.79% |
| % of Gross Profit | ||
| Operating Expenses | $65.73M | $72.42M |
| YoY Change | 18.43% | 54.14% |
| Operating Profit | -$65.67M | -$71.90M |
| YoY Change | 30.91% | 63.07% |
| Interest Expense | $3.530M | $4.297M |
| YoY Change | -31.32% | 12.75% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $3.525M | $4.296M |
| YoY Change | -31.47% | -61471.43% |
| Pretax Income | -$62.14M | -$67.61M |
| YoY Change | 38.03% | 67.8% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$62.14M | -$67.61M |
| YoY Change | 38.03% | 67.8% |
| Net Earnings / Revenue | -101870.49% | -13178.75% |
| Basic Earnings Per Share | -$0.75 | -$0.82 |
| Diluted Earnings Per Share | -$0.75 | -$0.82 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 82.48M shares | 82.24M shares |
| Diluted Shares Outstanding | 82.49M shares | 82.31M shares |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $265.1M | $279.1M |
| YoY Change | -24.17% | -35.39% |
| Cash & Equivalents | $95.83M | $64.44M |
| Short-Term Investments | $169.3M | $214.7M |
| Other Short-Term Assets | $5.925M | $6.998M |
| YoY Change | -10.23% | 4.07% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $126.0K | $244.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $271.1M | $286.4M |
| YoY Change | -24.39% | -35.06% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $15.42M | $14.16M |
| YoY Change | 33.39% | -70.3% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $0.00 | $39.20M |
| YoY Change | -100.0% | -18.45% |
| Other Assets | $5.281M | $8.145M |
| YoY Change | -8.24% | 55.05% |
| Total Long-Term Assets | $56.43M | $98.45M |
| YoY Change | -61.36% | -2.5% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $271.1M | $286.4M |
| Total Long-Term Assets | $56.43M | $98.45M |
| Total Assets | $327.6M | $384.8M |
| YoY Change | -35.09% | -29.0% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $12.49M | $13.77M |
| YoY Change | 19.98% | 70.7% |
| Accrued Expenses | $28.79M | $27.67M |
| YoY Change | -4.93% | -27.62% |
| Deferred Revenue | $14.68M | $14.68M |
| YoY Change | 78.62% | 78.62% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $72.35M | $74.31M |
| YoY Change | 23.46% | 36.31% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $3.281M | $3.768M |
| YoY Change | -96.17% | -95.69% |
| Total Long-Term Liabilities | $3.281M | $3.768M |
| YoY Change | -96.17% | -95.69% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $72.35M | $74.31M |
| Total Long-Term Liabilities | $3.281M | $3.768M |
| Total Liabilities | $151.9M | $152.8M |
| YoY Change | 5.37% | 7.57% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.400B | -$1.400B |
| YoY Change | 16.67% | 16.67% |
| Common Stock | $1.598B | $1.593B |
| YoY Change | 1.51% | 1.51% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $175.6M | $232.0M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $327.6M | $384.8M |
| YoY Change | -35.09% | -29.0% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$62.14M | -$67.61M |
| YoY Change | 38.03% | 67.8% |
| Depreciation, Depletion And Amortization | $1.599M | $1.420M |
| YoY Change | 5.2% | -7.79% |
| Cash From Operating Activities | -$52.59M | -$57.06M |
| YoY Change | 48.3% | 47.41% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $2.921M | $3.494M |
| YoY Change | 1117.08% | 162.12% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $86.90M | $55.45M |
| YoY Change | -184.71% | 287.34% |
| Cash From Investing Activities | $83.98M | $51.95M |
| YoY Change | -181.68% | 300.2% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 0.000 | 322.0K |
| YoY Change | -99.73% | |
| NET CHANGE | ||
| Cash From Operating Activities | -52.59M | -57.06M |
| Cash From Investing Activities | 83.98M | 51.95M |
| Cash From Financing Activities | 0.000 | 322.0K |
| Net Change In Cash | 31.39M | -4.786M |
| YoY Change | -122.7% | -105.21% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$52.59M | -$57.06M |
| Capital Expenditures | $2.921M | $3.494M |
| Free Cash Flow | -$55.51M | -$60.56M |
| YoY Change | 55.49% | 51.22% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
513000 | usd |
| CY2023Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
2887000 | usd |
| CY2024Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
54210000 | usd |
| CY2023Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
29779000 | usd |
| CY2024Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
18206000 | usd |
| CY2023Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
17202000 | usd |
| CY2024Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
72416000 | usd |
| CY2023Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
46981000 | usd |
| CY2024Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-71903000 | usd |
| CY2023Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-44094000 | usd |
| CY2024Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1000 | usd |
| CY2023Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-7000 | usd |
| CY2024Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
4297000 | usd |
| CY2023Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
3811000 | usd |
| CY2024Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
4296000 | usd |
| CY2023Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3804000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-67607000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-40290000 | usd |
| CY2024Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.82 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.58 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.58 | ||
| CY2024Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
82310368 | shares |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
82310368 | shares |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-67607000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-40290000 | usd |
| CY2024Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-116000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-6000 | usd |
| CY2024Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-67723000 | usd |
| CY2023Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-40296000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
349097000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
11000 | usd |
| CY2024Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.82 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.56 | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
5365000 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3173000 | usd | |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
81767263 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
81767263 | shares |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.56 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
192000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7585000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-524000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-61950000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
294400000 | usd |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5010000 | usd |
| CY2024Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2024Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
322000 | usd |
| CY2024Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-116000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-67607000 | usd |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
232009000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
360680000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4507000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
1322000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-49036000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
317473000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
117079000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5215000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
435000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-6000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-40290000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
399917000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-129557000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-89326000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12595000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9722000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
2829000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
3084000 | usd | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | usd | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-1583000 | usd | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
3596000 | usd | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
1473000 | usd | |
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
415000 | usd | |
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
0 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-9943000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2859000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-535000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-611000 | usd | |
| edit |
Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
|
3271000 | usd | |
| edit |
Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
|
-8837000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-443000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
0 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
5967000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1256000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-6538000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-2360000 | usd | |
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
2162000 | usd | |
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-6760000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
1969000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
0 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-106934000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-74479000 | usd | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
86221000 | usd | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
68183000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
138795000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
107605000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
47209000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
36249000 | usd | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | usd | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
117079000 | usd | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
192000 | usd | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
11000 | usd | |
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
322000 | usd | |
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
435000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
514000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
117525000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-59211000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
79295000 | usd | |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
127529000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
145399000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
68318000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
224694000 | usd |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
64441000 | usd |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
220817000 | usd |
| CY2024Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
3877000 | usd |
| CY2023Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
3877000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
68318000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
224694000 | usd |
| CY2024Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
3877000 | usd |
| CY2023Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
3877000 | usd |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
54000 | usd | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
212000 | usd | |
| edit |
Non Cash Transactions Offering Cost Included In Accounts Payable And Accrued Expenses
NonCashTransactionsOfferingCostIncludedInAccountsPayableAndAccruedExpenses
|
0 | usd | |
| edit |
Non Cash Transactions Offering Cost Included In Accounts Payable And Accrued Expenses
NonCashTransactionsOfferingCostIncludedInAccountsPayableAndAccruedExpenses
|
230000 | usd | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
7683000 | usd | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
5738000 | usd | |
| edit |
Remeasurement Of Operating Lease Liabilities And Right Of Use Assets Due To Lease Modification
RemeasurementOfOperatingLeaseLiabilitiesAndRightOfUseAssetsDueToLeaseModification
|
794000 | usd | |
| edit |
Remeasurement Of Operating Lease Liabilities And Right Of Use Assets Due To Lease Modification
RemeasurementOfOperatingLeaseLiabilitiesAndRightOfUseAssetsDueToLeaseModification
|
1069000 | usd | |
| edit |
Commencement Of Right Of Use Asset
CommencementOfRightOfUseAsset
|
7844000 | usd | |
| edit |
Commencement Of Right Of Use Asset
CommencementOfRightOfUseAsset
|
0 | usd | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
Nature of Business<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Editas Medicine, Inc. (the “Company”) is a clinical stage gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a wholly-owned subsidiary of the Bristol-Myers Squibb Company (“BMS”), payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”) and payments received in connection with the Company’s license agreement with Vertex Pharmaceuticals, Inc. (“Vertex”).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2023, the Company completed a public offering in which it sold 12,500,000 shares of its common stock and received net proceeds of approximately $117.1 million after deducting underwriting discounts and commissions and other offering costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021, the Company entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). The Company amended the common stock sales agreement with Cowen in February 2024 in connection with filing a new registration statement. As of June 30, 2024, the Company has not sold any shares of its common stock under the ATM Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred annual net operating losses in every year since its inception. As of August 7, 2024, the issuance date of the consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the consolidated financial statements. The Company had an accumulated deficit of $1.4 billion at June 30, 2024, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</span></div> | ||
| CY2024Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1400000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
318749000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
18000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
460000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
318307000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
426937000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
611000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
413000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
427135000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
|
15 | security |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
40000.00 | usd |
| CY2024Q2 | edit |
Marketable Securities Noncurrent Number Of Securities
MarketableSecuritiesNoncurrentNumberOfSecurities
|
5 | security |
| CY2024Q2 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
39200000 | usd |
| edit |
Marketable Securities Remaining Maturity Term
MarketableSecuritiesRemainingMaturityTerm
|
P1Y | ||
| us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | usd | |
| us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | usd | |
| CY2024Q2 | edit |
Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
|
15879000 | usd |
| CY2023Q4 | edit |
Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
|
16204000 | usd |
| CY2024Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8130000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11280000 | usd |
| CY2024Q2 | edit |
Sublicense And License Fees
SublicenseAndLicenseFees
|
540000 | usd |
| CY2023Q4 | edit |
Sublicense And License Fees
SublicenseAndLicenseFees
|
5063000 | usd |
| CY2024Q2 | edit |
Intellectual Property And Patent Related Fees
IntellectualPropertyAndPatentRelatedFees
|
1975000 | usd |
| CY2023Q4 | edit |
Intellectual Property And Patent Related Fees
IntellectualPropertyAndPatentRelatedFees
|
983000 | usd |
| CY2024Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
530000 | usd |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
750000 | usd |
| CY2024Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
615000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
283000 | usd |
| CY2024Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
27669000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
34563000 | usd |
| CY2024Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
43118000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
38292000 | usd |
| CY2024Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
28962000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
26260000 | usd |
| CY2024Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14156000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
12032000 | usd |
| CY2023Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
10187000 | usd |
| edit |
Accounts Receivable Additions
AccountsReceivableAdditions
|
271000 | usd | |
| edit |
Accounts Receivable Deductions
AccountsReceivableDeductions
|
10214000 | usd | |
| CY2024Q2 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
244000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
68888000 | usd |
| edit |
Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
|
0 | usd | |
| edit |
Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
|
0 | usd | |
| CY2024Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
68888000 | usd |
| CY2024Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5010000 | usd |
| CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5215000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
12595000 | usd | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9722000 | usd | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10887151 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8271419 | shares | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |
